Mon, November 8, 2021
Sun, November 7, 2021
Fri, November 5, 2021
Thu, November 4, 2021
Wed, November 3, 2021
Tue, November 2, 2021

Gil Blum Maintained (SRPT) at Strong Buy with Decreased Target to $157 on, Nov 4th, 2021


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. ith-decreased-target-to-157-on-nov-4th-2021.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Gil Blum of Needham, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy with Decreased Target from $166 to $157 on, Nov 4th, 2021.

Gil has made no other calls on SRPT in the last 4 months.



There are 6 other peers that have a rating on SRPT. Out of the 6 peers that are also analyzing SRPT, 3 agree with Gil's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Judah Frommer of "Credit Suisse" Maintained at Hold with Decreased Target to $95 on, Friday, October 15th, 2021
  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Decreased Target to $90 on, Monday, August 16th, 2021
  • Anupam Rama of "JP Morgan" Upgraded from Sell to Hold and Decreased Target to $87 on, Thursday, August 5th, 2021


These are the ratings of the 3 analyists that currently disagree with Gil


  • Yun Zhong of "BTIG" Maintained at Strong Buy with Increased Target to $125 on, Tuesday, October 12th, 2021
  • Whitney Ijem of "Guggenheim" Upgraded from Hold to Strong Buy on, Wednesday, September 15th, 2021
  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Decreased Target to $122 on, Thursday, August 5th, 2021

Publication Contributing Sources